T 0400/97 (Immunoglobulins/CELLTECH) du 24.05.2000
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2000:T040097.20000524
- Date de la décision
- 24 mai 2000
- Numéro de l'affaire
- T 0400/97
- Requête en révision de
- -
- Numéro de la demande
- 84301996.9
- Classe de la CIB
- C12N 15/63
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- Processes for the production of multichain polypeptides or proteins
- Nom du demandeur
- Celltech Therapeutics Limited
- Nom de l'opposant
- Boehringer Ingelheim GmbH
Genentech, Inc.
Eli Lilly and Company
Pharmacia & Upjohn AB
Protein Design Labs, Inc.
Roche Diagnostics GmbH - Chambre
- 3.3.04
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 83 1973European Patent Convention Art 87 1973European Patent Convention Art 88 1973
- Mots-clés
- Oral presentation - state of the art (no)
Main request - sufficiency of disclosure (no)
First auxiliary request - sufficiency of disclosure (yes)
First auxiliary request - priority right (yes)
First auxiliary request - novelty and inventive step (yes)-not disputed - Exergue
- The information content made publicly available by a lecture cannot be put beyond reasonable doubt by any evidence of the lecturer alone, as the lecturer is in a quite different position to a member of the audience (see point 3 ff).
- Affaires citantes
- T 1212/97
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside
2. The case is remitted to the first instance with the order to maintain the patent on the basis of the set of claims and description submitted as first auxiliary request on 24 May 2000 and the drawings as granted.